期刊文献+

初诊2型糖尿病患者血清胆碱酯酶与三酰甘油的相关性研究

Association of plasma cholinesterase and triglyceride level in patients with newly diagnosed type 2 diabetes
原文传递
导出
摘要 目的探讨初诊2型糖尿病患者血清胆碱酯酶水平(ChE)与三酰甘油(TG)的相关性。方法收集2018年1月至2020年6月同济大学附属普陀人民医院收治的321例新诊断2型糖尿病患者的临床资料及生化指标。将ChE水平按四分位数分为Q1组(<6 915 U/L)81例、Q2组(6 916~8 268 U/L)80例、Q3组(8 269~9 578 U/L)80例、Q4组(≥9 579 U/L)80例, 分析血清ChE与TG的相关性。结果随着血清ChE的升高, TG水平显著升高(P<0.001)。相关分析结果显示ChE与体重、体重指数、TG、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、尿酸(UA)、丙氨酸氨基转氨酶(ALT)、天冬氨酸氨基转移酶(AST)均呈正相关(r分别为0.35、0.39、0.35、0.31、0.27、0.24、0.25、0.11, P<0.05、P<0.01或P<0.001), ChE与年龄、收缩压、血尿素氮(BUN)、肌酐、糖化白蛋白(GA)呈负相关(r分别为-0.46、-0.14、-0.20、-0.14、-0.21, P<0.05或P<0.001)。多元逐步回归分析显示血清ChE是TG独立影响因素(β值为0.270, P<0.001)。Logistic回归分析显示, 在校正性别、年龄、体重、血红蛋白、白细胞、总蛋白、白蛋白、球蛋白、ALT、BUN、肌酐、尿酸、吸烟史、饮酒史、HbA1C、GA、TC、LDL-C后, Q4组发生高TG血症风险是Q1组的6.024倍(P=0.011)。以TG 1.7 mmol/L为切点, 新诊断2型糖尿病患者血清ChE与高TG血症的受试者工作特征(ROC)曲线显示糖尿病ChE的最佳切点值为7 801 U/L。结论初诊2型糖尿病患者血清ChE与TG呈正相关。 Objective To investigate the relationship of plasma cholinesterase(ChE)with triglyceride(TG)levels in newly diagnosed patients with type 2 diabetes(T2DM).Methods Clinical data and biochemical parameters of 321 patients with newly diagnosed T2DM admitted to the Department of Endocrinology of People′s Hospital of Shanghai Putuo from January 2018 to June 2020 were retrospectively collected.The patients were classified into four groups based on the plasma ChE level:Q1group(n=81,<6915 U/L),Q2 group(n=80,6916-8268 U/L),Q3 group(n=80,8269-9578 U/L),and Q4 group(n=80,≥9579 U/L).The correlation of plasma ChE with TG level was analyzed.Results With the increased ChE level,TG level significantly increased(P<0.001).Correlation analysis showed that ChE was positively correlated with body weight,body mass index(BMI),TG,total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),uric acid(UA),alanine aminotransferase(ALT),aspartate aminotransferase(AST)(r=0.35,0.39,0.35,0.31,0.27,0.24,0.25,0.11,P<0.05,P<0.01 or P<0.001)while negatively correlated with age,systolic blood pressure,blood urea nitrogen(BUN),creatinine,and glycated albumin(GA)(r=-0.46、-0.14、-0.20、-0.14、-0.21,P<0.05 or P<0.001).Multivariate stepwise regression analysis showed that ChE was an independent risk factor for TG(β=0.270,P<0.001).Logistic Multivariate regression analysis showed that after adjustment for sex,age,body weight,hemoglobin,leukocytes,total protein,albumin,globulin,ALT,BUN,creatinine,uric acid,smoking history,drinking history,HbA1C,GA,TC,and LDL-C,the risk of hypertriglyceridemia in Q4 was 6.024 folds higher than Q1 group(P=0.011).With the TG(1.70 mmol/L)as cut-off value,the optimal cut-off point of the ChE was 7801 U/L,as calculated by receiver operating characteristic(ROC)curve analysis of ChE and hypertriglyceridemia.Conclusions ChE level is positively correlated with TG in newly diagnosed patients with T2DM.
作者 王广宇 王坤伟 谭姣容 陈焕珍 张立娟 杨昕 Wang Guangyu;Wang Kunwei;Tan Jiaorong;Chen Huanzhen;Zhang Lijuan;Yang Xin(Department of Endocrinology,Putuo People′s Hospital of Shanghai,Tongji University,Shanghai 200060,China;Department of Endocrinology,Shanghai Tianyou Hospital,Tongji University,Shanghai 200331,China)
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2022年第7期583-588,共6页 Chinese Journal of Endocrinology and Metabolism
关键词 胆碱酯酶 糖尿病 2型 三酰甘油 Cholinesterase Diabetes mellitus,type 2 Triglyceride
  • 相关文献

参考文献2

二级参考文献20

  • 1Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evoloc- umab (AMG 145) ,a fully human monoclonal antibody to PCSKg,in hyperlipidacmic patients on various background lipid therapies:pooled analysis of 1359 patients in four phase 2 trials [ J]. Europ Heart J, 2014,35 ( 33 ) :2249-2259. DOI : 10. 1093/eurheartj/ehu085. 2014.03.04.
  • 2Stein EA, Honarpour N, Wasserman SM, et al. Effect of the PCSK9 monoclonal antibody,AMG 145, in homozygous familial hyperchales- terolcmia[ J ]. Circulation,2013,128 (19) :2113-2120. DOI : 10.1161/CIRCULATIONAHA. 113. 004678. 2013.09.06.
  • 3Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hyperchol- esterolemia[ J]. Annu Rev Pharmacol Toxico1,2014 ,54 :273-293. DOI : 10. 1146/annurev-pharmtox-011613-140025. 2013.10. 16.
  • 4Alcantara VM, Chantard-Freire-Maia EA, Scartezini M, et al. Butyryl- cholinesterase activity and risk factors for coronary artery disease[ J]. Scand J Clin Lab Invest,2002,62(5) :399-404. DOI : 10. 1080/00365510260296564.
  • 5K~tlm6n J, Juh~z A, Rakonczay Z, et al. Increased serum butyrylcho- linesterase activity in type IIb hyperlipidaemic patients [ J ]. Life Sci, 2004,75 (10) : 1195-1204. DOI:10. 1016/j. lfs. 2004.02. 019.
  • 6Vallianou NG, Evangelopoulos AA, Bountziouka V, et al. Association of butyrylcholinesterasc with cardiometabolic risk factors among ap- parently healthy adults[ J ]. J Cardiovasc Med ( Hagerstown ), 2014, 15(5) :377-383. DOI : 10. 2459/JCM. 0b013e3283627700.
  • 7Manoharan I, Boopathy R, Darvesh S, et al. A medical health report on individuals with silent butyrylcholinesterase in the vysya community of India [ J ]. Clinica Chimica Acta,2007,378 ( 1-2 ) : 128 -135. DOI:10. 1016/j. cca. 2006.11. 005.
  • 8David SM, Soundararajan L, Boopathy R. The allele frequency of 'P920C mutation in hutyrylcholinesterase gene is high in an Indian population [ J ]. Gene, 2015,555 ( 2 ) :409-413. DOI:I0. 1016/j. gene. 2014.11. 040. 2014.11.20.
  • 9Huang YJ, Huang Y, Baldassarre H, et al. Recombinant human bu- tyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning[ J]. Proc Natl Acad Sci U S A,2007,104 (34) :13603-13608. DOI : 10. 1073/pnas. 0702756104.
  • 10Lamp6n N, Hermida-Cadahia EF, Riveiro A, ct al. Association be- tween butyrylcholinesterase activity and low-grade systemic inflamma- tion[ J]. Ann Hepato1,2012,11 ( 3 ) :356-363.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部